Advances in oral peptide therapeutics
If gut dysfunction contributes to metabolic problems, improving gastrointestinal health could theoretically support weight management
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
They watch your progress and tweak your treatment as needed
Many patients notice improvement in pain, mobility, or recovery within 13 weeks
Overall, aside from potential hypersensitivity, there are no absolute contraindications to biotin therapy on record